GMAB icon

Genmab (GMAB)

NASDAQ

$26.04

-$0.33 (

-1.25%

)

1D
5D
1M
6M
1Y
5Y
Pre market

GMAB: $26.04 / ₿ 0.0003 BTC / 33937 Sats

1D
5D
1M
6M
1Y
5Y

Key statistics

$26.37
$20.14 - $35.43
$15.99B
9.26
$790.00
613.93M
20.05
$25.95 - $25.99
Yes

What is Genmab (GMAB)?

Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.

The Genmab (GMAB) stock price has been falling

The Genmab A/S ADS (GMAB) stock pre-market price today is $26.04, reflecting a -1.25% pre-market move since the market last closed. The company’s market capitalization stands at $15.99B, with a daily trading volume of $790.00 shares. The previous closing price was $26.37.

Get started with Genmab (GMAB)

Ready to get started? Follow the steps below, or read our guide on how to buy Genmab stock on Kraken starting from $10.

Create an account

Create an account

Open the Kraken app to confirm your eligibility and follow the steps for account verification.



Deposit funds

Deposit funds

Once your account has been verified and stock trading is unlocked, you can deposit funds into your account using your preferred payment method.

Buy

Buy GMAB

Search for GMAB in the Kraken app, enter the amount you want to invest, review the important details and tap Confirm to place an order to buy GMAB.

GMAB FAQs

GMAB is in the Healthcare sector. Sector is a broad classification that groups companies based on their business activities, industry focus or economic function.

GMAB is in the Biotechnology industry. Industry is a more specific classification within a sector, grouping companies that operate in a similar field and have closely related business models.

Over the past 52 weeks, Genmab A/S ADS (GMAB) has traded between a low of $20.14 and a high of $35.43.

GMAB is in the Biotechnology industry group. Industry group is a further subdivision within an industry, grouping companies with even more closely related business models and operations. This helps investors analyze stocks at a more detailed level than sector and industry classifications alone.

Want to invest in Genmab? 
Get the Kraken app

Eligible US clients can now invest in over 11,000 stocks and ETFs - commission-free* - directly in the Kraken app. Download it and get started.

Fictional stock
USD icon
USD
GMAB icon
GMAB

Only available to USA clients through the Kraken app
or Kraken Pro.

Explore other stocks

Most active

Explore the most-traded stocks today

Top gainers

Browse today’s biggest stock market winners

AMST icon

AMST

ORGNW icon
MTVA icon

MTVA

Top losers

Compare the worst-performing stocks of 
the day

YOTAR icon

YOTAR

VSTD icon

VSTD

BTMWW icon
SAGT icon

Want to learn more about equities?

Check out our Kraken Learn Center guides

Currently available in the U.S. only; may not be available in all states. Brokerage services are provided by Kraken Securities LLC, member FINRA/SIPC. Please view the firm’s profile, registration and background of our registered reps on https://brokercheck.finra.org/. Digital asset services offered by Payward Interactive, not a member of FINRA/ SIPC and not FDIC insured. This is not an offer, solicitation, inducement or advice to buy or sell securities, or open a brokerage account in any jurisdiction where Kraken Securities is not registered. All trading involves risk, including loss of your investments. View full disclosures at: Equities Disclosures and Crypto Risk Disclosures.

*Other applicable fees may apply.